Clinical trial NCT04690166: Validation of the Turkish Translation of the London Speech Evaluation Scale
Official title: Validation and Cultural Adaptation of the Turkish Translation of the London Speech Evaluation Scale
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Speech Intelligibility
Speech Disorders
Head and Neck Cancer
Speech Dysfunction
Speech
Keywords: Perceptual
speech
articulation
neck
cancer
Lead sponsor: Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Sponsor class: OTHER
First posted: 2020-12-30
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adults with oral, oropharyngeal cancer and healthy adults

Brief summary: Purpose of the study is the validation and cultual adaptation of the Turkish translation of the London Speech Evaluation Scale (LSE-T), so that it would be used as an assessment tool for Turkish head and neck cancer patients. There is no validated Turkish version of LSE to measure severity of perceptual speech in head and neck cancer patients.

Detailed description: The speech function is a multidirectional process that depends on complex neuro-muscular network. The function can be evaluated using instrumental, such as voice analysis computer programmes, scales, or well structured questionnaires. There are many scales for assessment of perceptual speech but there is no validated for head and neck patients. The study will assess the construct validity and adaptation of the Turkish translation of Speech Specific Perceptual Speech Evaluation as known as London Speech Evaluation Scale. The investigators developed the Turkish translation of this scale (LSE-T), according to the cross-cultural adaptation guidelines. Two translators translated the LSE into Turkish and a native English language speaker reverse-translated it into English. The back translation was sent to the original author for proofreading. The LSE scale consisted of 6 parameters and 4 scores related with perceptual speech in head and neck cancer patients.

Eligibility criteria: Inclusion Criteria:

* Able to speak, read, understand and write in Turkish
* History of oral, orofarengeal cancer
* Volunteers who accept the informed consent

Exclusion Criteria:

* Mental disorders
* Cognitive limitations
* Able not to speak, read, understand and write in Turkish
* Underwent any surgery last six month
* Permanent tracheostomy, total laryngectomy
* Pregnancy
* Out of age 18-70 years old
* Adults who do not accept the informed consent.

Primary outcomes:
measure: Validation of the Turkish Translation of London Speech Evaluation Scale
timeFrame: Baseline
measure: Validation of the Turkish Translation of London Speech Evaluation Scale
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Prof Dr Cemil Tascioglu City Hospital
Study officials:
affiliation: Anadolu Medical Center, In Affiliation with Johns Hopkins Medicine
name: Ziya Salturk, Asso Prof,MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Dwivedi RC, Rose SS, Chisholm EJ, Kerawala CJ, Clarke PM, Nutting CM, Rhys-Evans PH, Harrington KJ, Kazi R. Development and validation of first-ever speech-specific perceptual speech evaluation tool for patients with head and neck cancer: the London speech evaluation (LSE) scale. Head Neck. 2012 Jan;34(1):94-103. doi: 10.1002/hed.21683. Epub 2011 Apr 5.